Ad
related to: alpha-glucosidase inhibitors for diabetes mechanism of action
Search results
Results from the WOW.Com Content Network
Examples of alpha-glucosidase inhibitors include: Acarbose- Precose or Glucobay; Miglitol – Glyset; Voglibose; Even though the drugs have a similar mechanism of action, there are subtle differences between acarbose and miglitol. Acarbose is an oligosaccharide, whereas miglitol resembles a monosaccharide. Miglitol is fairly well absorbed by ...
3.1 Mechanism of action. 3.2 ... is an anti-diabetic drug used to treat diabetes mellitus ... A 2016 meta-analysis confirms that alpha-glucosidase inhibitors ...
The studies enhanced knowledge of the mechanism by which α-glucosidase binds to imino sugars. [19] Diabetes: Acarbose, an α-glucosidase inhibitor, competitively and reversibly inhibits α-glucosidase in the intestines. This inhibition lowers the rate of glucose absorption through delayed carbohydrate digestion and extended digestion time.
Alpha-glucosidase inhibitors are a class of diabetes drugs found in plants/herbs like cinnamon; [3] however, they are technically not hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, such that glucose from the starch enters the ...
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. [1] Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup A10 is part of the anatomical group A Alimentary tract and ...
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
Thiazolidinedione ligand dependent transactivation is responsible for the majority of anti-diabetic effects. The activated PPAR/RXR heterodimer binds to peroxisome proliferator hormone response elements upstream of target genes in complex with a number of coactivators such as nuclear receptor coactivator 1 and CREB binding protein, this causes upregulation of genes (for a full list see PPARγ):
Ad
related to: alpha-glucosidase inhibitors for diabetes mechanism of action